Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14733553 | 0.81 | MDM4 (0.37) | HDAC1HDAC2 | |
| SCHEMBL14716482 | 0.76 | BACE1 (0.47) | BACE1LMNANPC1 | |
| SCHEMBL15839804 | 0.74 | EPHX1 (0.39) | BACE1LMNAKDM4ENPC1 | |
| SCHEMBL15839953 | 0.73 | ALDH1A1 (0.42) | BACE1LMNANPC1 | |
| SCHEMBL15839806 | 0.73 | EPHX1 (0.39) | BACE1LMNAKDM4ENPC1 | |
| SCHEMBL7918847 | 0.71 | KMT2A (0.36) | — | |
| SCHEMBL14733552 | 0.71 | BACE1 (0.45) | BACE1CNR1HDAC1HDAC2 | |
| SCHEMBL15839986 | 0.71 | EPHX1 (0.38) | BACE1LMNAKDM4ENPC1 | |
| SCHEMBL15839941 | 0.71 | EPHX1 (0.38) | BACE1LMNAKDM4ENPC1 | |
| SCHEMBL16664351 | 0.71 | EPHX1 (0.42) | LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550795-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-2751116-B1 | HEXAHYDROPYRANO [3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20150087637-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-8933221-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2751116-A1 | HEXAHYDROPYRANO [3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS | Pfizer Inc (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013030713-A1 | HEXAHYDROPYRANO [3,4-D][1,3] THIAZIN-2-AMINE COMPOUNDS | PFIZER INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130053373-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | BRODNEY MICHAEL AARON (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053373-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | DPYD, TPMT, QDPR | BACE1 3093/4885HTT 439/4885LMNA 3515/4885 |
| US-20150087637-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | DPYD, TPMT, QDPR | BACE1 3093/4885HTT 439/4885LMNA 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.